{
    "clinical_study": {
        "@rank": "110926", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541 - Source 1", 
                "arm_group_type": "Experimental", 
                "description": "Each healthy participant will receive a single subcutaneous (SQ) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of three treatment periods"
            }, 
            {
                "arm_group_label": "LY2605541 - Source 2", 
                "arm_group_type": "Experimental", 
                "description": "Each healthy participant will receive single SQ injection of 0.5 U/kg of LY2605541 on Day 1 of one of three treatment periods"
            }, 
            {
                "arm_group_label": "LY2605541 - Source 3", 
                "arm_group_type": "Experimental", 
                "description": "Each healthy participant will receive single SQ injection of 0.5 U/kg of LY2605541 on Day 1 of one of three treatment periods"
            }
        ], 
        "brief_summary": {
            "textblock": "This study looks at the amount of LY2605541 in the body after it is injected under the skin.\n      The study has 3 periods, each lasting 10 days. Each participant will receive one injection\n      in each period. At least 14 days will pass between each injection."
        }, 
        "brief_title": "A Study of LY2605541 in Healthy Participants", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are overtly healthy males or females, as determined by medical history and physical\n             examination\n\n          -  A body mass index of 18.5 to 30 kilograms per meter square (kg/m^2)\n\n        Exclusion Criteria:\n\n          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal, endocrine, hematological, or neurological disorders capable of\n             significantly altering the absorption, metabolism, or elimination of drugs; of\n             constituting a risk when taking the study medication; or of interfering with the\n             interpretation of data\n\n          -  Are women with a positive pregnancy test or are women who are lactating\n\n          -  Intend to use over-the-counter medication within 7 days prior to dosing or\n             prescription medication within 14 days prior to dosing (apart from contraceptive\n             medication, vitamin/mineral supplements, occasional acetaminophen, and/or hormone\n             replacement therapy)\n\n          -  Have donated blood of more than 500 milliliters (mL) within the last month\n\n          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14\n             units per week (females)\n\n          -  Are excessive consumers of xanthines (more than 10 cups of tea, coffee, cola or hot\n             chocolate per day)\n\n          -  Have a fasting blood glucose (BG) >110 milligrams per deciliter (mg/dL) (6.1\n             millimoles per liter [mmol/L])\n\n          -  Currently smoke more than 10 cigarettes per day, or are unwilling to refrain from\n             smoking for 72 hours prior to each dosing occasion and during confinement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877265", 
            "org_study_id": "14594", 
            "secondary_id": "I2R-MC-BIDH"
        }, 
        "intervention": {
            "arm_group_label": [
                "LY2605541 - Source 1", 
                "LY2605541 - Source 2", 
                "LY2605541 - Source 3"
            ], 
            "intervention_name": "LY2605541", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Assessment of the Impact of Monomethoxy Polyethylene Glycols on the Pharmacokinetics and Glucodynamics of Single Doses of LY2605541 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Time Curve from Zero to Infinity (AUC[0-\u221e]) of LY2605541", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 216 hours post dose in each period"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2605541", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 216 hours post dose in each period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Glucodynamics: Maximum Glucose Infusion Rate (Rmax)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 216 hours post dose in each period"
            }, 
            {
                "measure": "Glucodynamics: Total Amount of Glucose Infused (Gtot)", 
                "safety_issue": "No", 
                "time_frame": "Predose up to 216 hours post dose in each period"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}